T-67 days before @ascocancer.bsky.social #ASCO26! I am looking forward to the largest oncology event of the year and specifically to the multiple #globaloncology sessions 🌐scheduled throughout the meeting. See you all in #Chicago where you get to experience all these 🌞🍃🌧️ within a day! 😄

Great to hear Dr @herbloongmd.bsky.social speak about immunotherapy clinical trials at Apollo Proton Cancer Centre in Chennai, India.

Putting some last minute slides together 😂. Flight delayed from #HKG to #FRA so not sure whether we can make the transit, but #GütenMorgenAlles and see you in person at Berlin for @myESMO #ESMO25! #sarcoma #LCSM @ctosociety @apoddc @APCLC_2023

Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025

The @ascocancer.bsky.social #InternationalAffairsCommittee #2025-26. An absolute delight and pleasure working with these highly engaged professionals from across the world 🌎 and across oncology disciplines. #BestASCOCommittee

It's always a pleasure meeting #colleagues on home turf in #hongkong 🇭🇰 after a long day of clinic. #LCSM @cuhkmedicine.bsky.social

Whirlwind 2 days in #Manila at #PSMO @astra-zeneca.bsky.social 🫁 #lungcancer #preceptorship w/ colleagues & experts including @KSamalaMD #ArthurLui 🇵🇭 together w/ #QuincyChu of @AlbertaUni 🇨🇦. Covered broad topics: #targetedtherapies, #IO, #EGFR and #SCLC. #LCSM @cuhkmedicine.bsky.social @APCLC_2023

Enhancing cost-effectiveness considerations in the adoption of new drugs in Hong Kong www.hkmj.org/abstracts/v3...

#ImprovingAccess to #effectivetherapies is mandate all physicians should uphold. How to incorporate these whilst balancing societal costs require guidelines & discussions. Our position paper on "Enhancing cost-effectiveness considerations in adoption of new drugs in HK" www.hkmj.org/earlyrelease...

The Strong International Camaraderie Between Past and Present Fellows of the PMH Fellowship - Herbert Loong @herbloongmd.bsky.social @pmresearch-uhn.bsky.social oncodaily.com/blog/herbert... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PMHFellowship

🇭🇰🚝✈️🇨🇦🚗🏥=🤩 Looking forward to #returning to #Toronto & my alma mater @uhnresearch.ca #PrincessMargaretCancerCentre for a short visit this weekend! Very honoured and privileged to be able to give #GrandRounds 🎙️ Best way to fight jetlag! See you soon!👋 #LCSM #Sarcoma #CUHKSarcoma #precisiononcology

Putting final touches together to my talk😀. Looking forward to welcoming you all to #hongkong 🇭🇰 for #ESMOTATAsia25! Don't be shy - come by and say hi! #drugdevelopment @cuhkmedicine.bsky.social @apoddc @APCLC_2023

#PublicEducation on #sarcomas can be fun! 😃 #facialkexpressions #CannotHideHit #HappyMonday #CUHKSarcoma youtu.be/XesQlcQPMOY?...

One week until the inaugural #ESMOTATAsia25 🤩 I'm looking forward to joining global drug development experts in🍜🇭🇰 + sharing insights on dose optimisation of novel combinations 🗓️ Saturday 19 July 2pm. @myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social

Incorporating high-risk individuals beyond smoking history into lung cancer screening in Hong Kong: a cost-effectiveness study - JTO Clinical and Research Reports www.jtocrr.org/article/S266...

Thanks @liferaftgroup.bsky.social for opportunity to share some key #GIST updates from #ASCO25 w/ wider patients' community 🌎 through this webinar last week. @srothschild @cuhkmedicine.bsky.social @GISTNetwork @ctosociety #DrugDevelopment #sarcomas #CUHKSarcoma youtu.be/uoZULT8YlPU?...

Come join us in a couple of hours as we discuss several #abstracts related to #GISTs presented at #ASCO25! Registration is free! Register here: us02web.zoom.us/webinar/regi... @liferaftgroup.bsky.social @ctosociety #sarcoma @cuhkmedicine.bsky.social #CUHKSarcoma #PublicEducation

After serving on #MembershipCommittee, I look forward to returning to #CommunicationsCommittee @iaslc.bsky.social w/ #LCSM colleagues from around the World 🌐 to create #effective, #efficient & #robust channels of communications between our society & community. @CUHKMedicine @apoddc @APCLC_2023

Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC #lungcancer #NSCLC #ASCO25 @herbloongmd.bsky.social @ascocancer.bsky.social www.onclive.com/view/sevaber...

#Honoured and #humbled to have been awarded #FASCO at @ascocancer.bsky.social #ASCO25. My thanks to my friends and colleagues for your overwhelming support along the way 😊 #sarcoma #LCSM #InternationalAffairsCommittee #drugdevelopment #precisiononcology

T-13hrs 59mins before landing in #Chicago for @ascocancer.bsky.social #ASCO25! ✈️ full of oncology colleagues from 🇭🇰🇵🇭 and from 🇦🇺🦘🐨😀. What’s the combined H-index of this flight? 🧐 Looking fwd to days of #scientificexchanges and #interactivediscussions. Safe travels everyone! See you at McCormick!

As @ascocancer.bsky.social #ASCO25 is round the corner, so is the end of my #chair of #InternationalAffairsCommittee. Tks all my colleagues & friends from around the World 🌍 for continuous support. Time to pass torch 🔥 to Dr. Monica Malik who will continue to push our global agenda forward!

Come join us in #hongkong 🇭🇰 🍜🥟🥡 for the #inaugural @myesmo.bsky.social #ESMOTATAsia25 on July 18-20, 2025! We have assembled a #stellar group of #international #faculties and #experts in #drugdevelopment to help move the field forward. Register today!

Thanks to Dr Herbert Loong, of The Chinese University of Hong Kong, for speaking with us during #AACR25 about the efficacy of D3S-001 in KRAS G12C inhibitor–resistant NSCLC! See our site for more meeting insights! @theaacr.bsky.social #lcsm #oncology www.onclive.com/conference/a...

Thanks my #coinvestigators for opportunity to present data of #D3S_001, a novel #KRASG12C inhibitor in #G12Ci pre-treated #NSCLC at @theaacr.bsky.social #AACR25. Strong & rapid #targetengagement confer superior #efficacy c.f. 1st generation G12Ci. ✔️ORR 30%; DCR 80% in KRASG12Ci pre-treated popn.

Better late than never! 🤣 Arrived in #Chicago for @theaacr.bsky.social #AACR25 after 14 hours flight ✈️ and looking forward to the #ClinicalTrials #Minisymposium tomorrow.

Wonderful opportunity to #share & #discuss emerging role of #TCellEngagers #BiTEs in Mx of #SCLC 🫁 w/ our Malaysian 🇲🇾 colleagues during #LCS2025. Small group discussions (esp. over a meal! 😋) are always very interactive for experience sharing. #LCSM @APCLC_2023 @apoddc @cuhkmedicine.bsky.social

📢The @ctosociety #SpringWebinar is taking place in < 72hours! Come join our #international faculty on #EwingSarcoma as we take deep dive into similarities and differences of this "same" disease in #paediatrics and #adults patients! Register today at: ctos.org/EducationalP... #CTOSTweeTOS #sarcoma

Thank you #LCS2025 in #KualaLumpur 🇲🇾 for hosting an informative & interactive lung cancer meeting! Always pleasure to meet colleagues who are keen to move our 🫁 field forward. #LCSM @apoddc @APCLC_2023 @stephanieplsaw @drdaviddwlee #BeungChulAhn #PJVoon #JenniferLeong @drsanjaypopat.bsky.social

@drsanjaypopat.bsky.social speaking on treatment landscape in #NSCLC and #SCLC beyond #immunotherapies in the era of #ADCs 💉at #LCS2025 in #KualaLumpur 🇲🇾. #LCSM #drugdevelopment @voonpeijye @davidlee

Heading to #KualaLumpur #Malaysia 🇲🇾 to meet #LCSM friends and colleagues at #LCS2025 🫁. Looking forward to some fruitful discussions and #NasiLemak! 😋 @drdaviddwlee @stephanieplsaw @APCLC_2023 @apoddc

Thrilled to have #friend & #collaborator @KaiKeenShiu of @ucl.ac.uk 🇬🇧 visit us in #hongkong 🇭🇰 these last few days, including a visit & talk specifically @cuhkmedicine.bsky.social this afternoon. Good to familiarise myself with updates in #GICancers as well! @StephenLChan1 @mollylisc #KaOnLam

Amazing #friends and #colleagues from around the #world! A fruitful #lungcancer and #culinary trip to #Taipei 🇹🇼. #LCSM

#lungcancer 🫁 is a global burden which needs to be addressed worldwide. Happy to share an archived #CME talk I gave to the #HongKong #Medical Association where I discussed the key considerations and implications for #lungcancer #screening in our region. youtu.be/4Z6XHz2CF4I?...

Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST | Journal of Clinical Oncology ascopubs.org/doi/10.1200/... @n8pennell.bsky.social @ascocancer.bsky.social @oncoalert.bsky.social

Happy to share our recent #ESMOOpen paper on the #safety and #feasibility of #outpatient administration of #tarlatamab as part of the #DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy. #LCSM 🫁 #SCLC 😀 doi.org/10.1016/j.es...

📢 Pleased to have launched #prospective #PUSH project on #LGFMS and #SEF last month. First #coordinated #multistakeholder #international effort 🌎 utilising this unique platform to study rare cancers 🦀. Video recording of our launch meeting is available here: push-platform.org/LGFMS_Study....

🔎CTOS Communications Committee is conducting a survey to understand your engagement w/ #socialmedia and understand your #communication needs! Your insights will help us improve our online presence and better serve our community. ⏳<5 min 💻https://surveymonkey.com/r/55GSVNV #Sarcoma #CTOSTweeTOS

Wonderful crew of #ESMORarecancer25 #YOCasesDiscussion session! Definitely not-so-young oncologists are also welcome. Great cases discussed and thanks everyone for contributing! @pawel_sobczuk @DrLizConnolly @Robertasanfili @RobinL_Jones @haileykcarroll and many others. #sarcoma #CTOSTweeTOS

Congrats to @amalsargsyan & @dmbranco.bsky.social for having abstracts selected for #oralpresentation at #ESMORarecancers25! Excellent work in helping community understand current issues w/ #sarcoma #clinicaltrials access & #impression of #realworldevidence for drug approvals. #drugdevelopment

We are kicking off @myesmo.bsky.social #ESMORareCancers25 in Lugano 🇨🇭 this morning! Looking forward to 3 days of interactions with experts in #sarcomas and other #rarediseases from around the 🌎. #CUHKSarcoma #CTOSTweeTOS

An honour to be in the same photo as both @ascocancer.bsky.social current- and president-elect 😀, together with other colleagues from around the 🌎 #globaloncology #InternationalAffairsCommittee

Norman Ng – a remarkable figure in the fight against cancer in Hong Kong - Jemma Arakelyan @drjemm.bsky.social oncodaily.com/blog/jemma-a... #Cancer #Medicine #Health #FightAgainstCancer #HongKong #Oncology #OncoDaily

Matt Krebs on NHS England ctDNA pilot To make ctDNA cost effective, tissue NGS testing in some patients needs to be stopped How do we (safely) do this? ❇️ Actionable Tier 1 mutation present ➡️ no tissue NGS confirmation needed ❇️ Non-informative ctDNA: still need tissue NGS ❗️Guidelines coming ❗️

Had to pleasure to welcome Fan Zhang, PhD & #hongkong #Pfizer team 🇭🇰 today brief visit to @CUHKMedicine Dept. Clinical Oncology. Long standing relationship working w/ Pfizer on multiple fronts in #drugdevelopment 💊. Looking forward to more collaborations. #LCSM #Sarcoma

Our February issue is live!🙌 Featuring #iGAS infections in Australia, Hong Kong #Genome Project, #Thalassemia Registry in Singapore, new #ML tool to guide cervical cancer screening & more! 🖋️Editorial: When #bushfires become the "new normal" 🎨Cover: Ms Desiree Tse from HKGI 🔗 tinyurl.com/ycydsrdz

Strengthening lung cancer screening in Hong Kong: policy, innovation, and collaborative approaches for early detection and improved outcomes www.hkmj.org/abstracts/v3...

Looking forward to an amazing #international #oncology event dedicated to #innovations and #advances in oncology care & research at @ascocancer.bsky.social #ASCOBT26 to be held in the dynamic city of #Singapore! 🇸🇬☀️🏖️. Mark your calendars! 🗓️ June 25-27, 2026. #InternationalAffairsCommittee

Always nice to meet #LCSM #friends from around the #world 🌎! Thanks @iaslc.bsky.social #TTLC25 for providing platform for collaborations, discussions & just hanging out! @vamsivelcheti.bsky.social @aaronmansfield.bsky.social @elaineshummd.bsky.social and many others! @apoddc @apclc @CUHKMedicine